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A B S T R A C T
Background
Duchenne muscular dystrophy (DMD) is the most common X-linked neuromuscular disorder. When boys with DMD reach the second decade
of life, they lose their ability to walk and become wheelchair dependent. Standing devices and orthoses are considered to be an essential
component in the therapy management of DMD. Clinical opinion and research from other neurological conditions highlight the proposed
benefits of standing device use, however, its effect within this population is currently unknown. A review of the evidence for the use of
standing devices and orthoses is necessary to inform all stakeholders, including people with DMD, clinicians, decision makers and funders,
and to guide future research.
Objectives
To assess the effects of standing devices and orthoses on musculoskeletal impairments (such as pain, contracture, scoliosis development
and bone density) in boys and men with DMD, and secondarily to determine their effect on quality of life, participation in activities, and
patient experience (satisfaction). We also considered any adverse events associated with their use.
Search methods
We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, AMED, PsycINFO, CINAHL Plus, PEDro, and
ProQuest Dissertations & Theses Global up to 5 September 2019. We checked references in identified trials, handsearched journal ab-
stracts, and searched trials registries.
Selection criteria
We planned to include randomised controlled trials (RCTs) and quasi-RCTs of any model of standing device for use in DMD. The control
interventions would have been any other comparison group, including no standing device, a different model of standing device, usual
care, or an alternative form of assistive weight bearing.
Data collection and analysis
We used standard Cochrane methodological procedures.
Main results
Although we identified 13 potentially relevant studies, none met the inclusion criteria for this review.
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Authors' conclusions
Since there were no RCTs or quasi-RCTs available to evaluate the effectiveness of standing devices in people with DMD, studies are needed
to investigate the effectiveness of standing devices in this population.
P L A I N   L A N G U A G E   S U M M A R Y
The use of standing devices for boys with Duchenne muscular dystrophy
Review question
What is the effect of using standing devices in boys with Duchenne muscular dystrophy (DMD)?
Background
DMD is a condition that affects only boys. The progressive muscle wasting that occurs with the condition results in decreased walking
ability and eventually, use of a wheelchair for mobility. Specialist equipment is used routinely to assist boys with DMD to stand or bear
weight. Such equipment includes standing devices (e.g. frames or standing wheelchairs) and orthoses (e.g. braces or splints). We have
evidence from other groups of people that standing reduces physical problems, including pain, development of contractures (fixed short-
ening of muscles) and curvature of the spine. Standing also strengthens bones. However, we have no evidence about the effects of the use
of standing frames or orthoses by boys and men with DMD.
We searched the medical literature for studies that met our inclusion criteria. We required studies to have assessed standing devices for use
in DMD compared to no standing device, a different model of standing device, usual care, or an alternative aid to enable weight bearing.
Studies had to randomly allocate participants to treatment groups (these studies usually provide the highest quality evidence).
Key results and quality of evidence
We found no studies that met our inclusion criteria.
Conclusion
We found no relevant trials eligible for this review to determine the effectiveness of standing devices for boys with DMD. We need further
studies to determine whether standing devices have an impact on specific health problems, participation in activities, and quality of life.
Future research studies should also focus on the 'dose' of standing (i.e. the duration, frequency and amount of weight bearing) and the
use of different orthoses.
The evidence is current to September 2019.
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B A C K G R O U N D
Description of the condition
Duchenne muscular dystrophy (DMD) is the most common X-linked
neuromuscular disorder, affecting approximately 1 in 3300 to 6000
live male births (Deconinck 2007; Mendell 2012). The underlying
causes are deletions, duplications and mutations in the dystrophin
gene. With recent advances in treatment, boys with this life-limiting
condition are now living into their fourth or even fiNh decades. By
contrast, few boys with DMD survived beyond their early twenties
in the past. Although boys may show symptoms of the condition at
an early stage, most are diagnosed around the age of five years. For-
mal diagnosis of DMD is typically through a combination of meth-
ods, including a clinical diagnosis of progressive muscle weakness,
family history and increased levels of creatine kinase in the blood
(Birnkrant 2018a). To provide a definitive diagnosis, genetic testing
via blood sampling is often performed, with or without a muscle
biopsy (Manzur 2008).
The predominant clinical presentation is wasting of the proximal
muscles, for example of the trunk, shoulder girdle, or both. Symp-
toms at presentation are either a delay in reaching typical motor
milestones (e.g. walking), or signs such as toe walking, poor mo-
tor skills, frequent falls, difficulty climbing stairs and a waddling
gait (Birnkrant 2018b). Fatigue and learning difficulties may also be
present. Although symptoms are often initially mild, there is a rapid
physical and functional decline due to progressive muscle wast-
ing (Kohler 2009). Once boys reach the second decade of life, they
lose their ability to walk, and become wheelchair dependent (Kinali
2007). At this time, a number of significant and complex secondary
comorbidities are often associated with the condition. These in-
clude the development of muscle contractures, osteoporosis, sco-
liosis, weight gain and respiratory complications, such as impaired
pulmonary function (Birnkrant 2018b). All of these comorbidities
can potentially be managed. Effective management of the condi-
tion and its comorbidities is required to enhance quality of life for
these children and their families.
Description of the intervention
Assisted standing involves using a device to help place load through
a person's feet. Boys and men with DMD achieve assisted stand-
ing via two main methods: standing devices (including standing
frames, standing wheelchairs and tilt tables) and orthoses. For the
purposes of this review, orthoses will only include hip-knee-an-
kle-foot orthosis (HKAFO), knee-ankle-foot orthoses (KAFO), and
standing shells. The two methods can be used both within the ther-
apy setting and in daily life in school or at home. Standing devices
and orthoses provide a stable mechanical support for weight bear-
ing in supine, prone or upright positions, depending on the de-
vice chosen; however, a precise and timely evaluation of individual
needs is required to select the most appropriate design of stand-
ing device, orthoses, or both. One survey of therapists reported
that 68% of them prescribed standing frames for people in the non-
ambulant stage of DMD (Eagle 2002). Traditionally, assisted stand-
ing devices are prescribed for non-ambulant DMD. However, their
use has been studied in both ambulant and non-ambulant children
aged 5 to 15 years of age (Taktak 1995).
Although there is a lack of conclusive evidence for the use of stand-
ing devices in DMD, clinical opinion and research from other neuro-
logical conditions (such as cerebral palsy), highlight the proposed
benefits (Caulton 2004; Pin 2007; Rivi 2014). These benefits include
preservation of muscle length and range of joint movement via the
stretch that occurs during standing (predominately of the hip and
lower-limb muscles) (Gibson 2009), delayed onset of scoliosis, in-
creased bone density (thereby reducing the risk of fractures) (Pope
2007), fewer muscle spasms and better respiratory function (in-
cluding voice control) (Glickman 2010). Research on standing for
other conditions has also suggested improved circulation, diges-
tion (Paleg 2008), and bowel and bladder function (Taylor 2009).
Clinical opinion on standing indicates other benefits, including
pressure relief (which improves skin integrity), improvement of
well-being and better sleep. However, these reported benefits have
not been systematically identified.
Standing devices are considered to be an essential component of
the therapy management of DMD (both physiotherapy and occupa-
tional therapy). Various other therapy techniques for DMD are used
alongside standing devices and are supported by research, includ-
ing massage and stretching and the use of adaptive equipment as
the disease progresses (Birnkrant 2018b). The use of standing de-
vices significantly increases once the ability to walk has been lost,
in order to maintain standing (Umphred 2013).
Access to the intervention
Access to neuromuscular services varies greatly depending upon
the person's location and age (paediatric versus adult services).
Physiotherapy and standing devices are typically provided during
childhood, but these services may now be required throughout
adolescence and adulthood, due to the increased life expectancy
of people with DMD.
How the intervention might work
Standing devices (supine standing frame, prone standing
frame, upright standing frame, tilt table, and standing
wheelchair)
A supine standing frame requires the person to lie down on the
frame before it is moved into a more upright position. The clinical
advantage of a standing frame is its use with those who lack an-
ti-gravity strength in their upper trunk, in addition to a reduction in
the amount of weight bearing. A prone standing frame places the
person in a forward tilt. This position encourages head control and
anti-gravity use of muscles in the upper trunk. A further clinical ad-
vantage of this frame is the ability to alter the amount of weight
bearing by changing the angle of tilt of the frame. This is impor-
tant for people with reduced leg strength or contractures. Provid-
ing an angle of tilt reduces the amount of leg strength and joint
range of movement required to maintain the position. An upright
standing frame places the person in an almost vertical position to
reflect a natural standing position. This has the benefit of achiev-
ing maximum weight bearing, which is important for bone density
(Umphred 2013).
A tilt table is very similar to a supine standing frame; however, the
person is placed on a large flat mat with straps across the chest,
hips and knees, rather than the more flexible fit of a supine stand-
ing frame. A tilt table provides similar clinical benefits to a supine
standing frame, but is less likely to be used in a home or classroom
setting because of its size.
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A standing wheelchair allows the person to complete functional
tasks in a standing position. The wheelchair can be either manual-
ly or power operated, and the height at which the person stands
can be adapted depending on the patient's current standing abili-
ty, taking into account any reduction in muscle length or range of
joint motion.
Orthoses
A HKAFO is a device that supports the entire lower limb. This is
achieved by providing support points at the hip, knee, ankle and
foot by either a metal or plastic design, in addition to a soN mater-
ial, for example leather, which is used for point-of-skin contact.
A KAFO is a device that supports the knee, ankle and foot with the
aim of maintaining alignment in the lower limb. In a similar man-
ner to the HKAFO, the KAFO is shaped to match the person’s limb,
either with a metal or plastic design and a soN material. These or-
thoses are reported to increase the length of time assisted walking
and standing can be maintained in DMD (Bakker 2000).
Standing shells are more commonly used by people with cerebral
palsy, to create optimal alignment of the body. A plaster cast is de-
veloped to encase the legs and back. A polyethylene plastic mould
is then created from the plaster cast. The plastic mould (standing
shell) is placed onto the person and secured in place by leather
straps. The standing shell allows people to complete functional
tasks in a standing position.
Variation in standing device and orthoses design and selection is
thus apparent, as is variation in the length of time spent using the
device. Currently there is insufficient evidence to determine the op-
timal dose for standing with standing devices and orthoses.
The presence of orthostatic hypotension, healing fractures and se-
vere contractures can prevent the use of standing devices (Holland
2006).
Potential limitations of the intervention
In this population, although there are many potential benefits to
using standing devices, it is important to recognise that there may
also be a number of possible disadvantages. These include the time
and commitment required on the part of the person and their fam-
ily to complete the intervention, and the possible associated finan-
cial costs to both the family and service provider, in terms of provi-
sion of equipment and adequately trained staH. Clinical disadvan-
tages associated with the use of standing devices include hypoten-
sion and boredom.
One aspect in determining the potential use of standing frames
is the degree of lower-limb contractures. Standing devices cannot
typically accommodate severe flexion contractures of the lower
limbs; additionally, weight bearing through the feet would result in
excessive abnormal forces being exerted through the lower limbs,
thus making a supported-standing programme inappropriate. Con-
tractures are more likely to be severe in individuals who have been
long-term wheelchair users, due to the length of time spent in sit-
ting postures and the consequent increased risk of contracture of
the hip flexor and hamstring musculature.
Why it is important to do this review
Despite clinical descriptions of the potential benefits of standing
devices and orthoses for this population and research in other pop-
ulations, there is no standardised approach to use of these devices
in people with DMD, and a lack of unequivocal evidence of their ef-
fectiveness (Eagle 2002). An expert consensus on the management
of DMD commented that the use of standing devices and orthoses is
logical, but not evidenced, and highlighted that there is no consen-
sus regarding how long they should be used for, or how frequently
(Dooner 2007).
One main issue in obtaining evidence for the use of standing de-
vices is that they may be used for many different reasons, so stud-
ies may focus on different potential benefits, adding to the com-
plexity of achieving consensus on their use. It is also necessary to
assess whether the potential advantages of assisted standing out-
weigh the previously described potential disadvantages in terms of
time, costs and clinical outcomes.
There is a clear need to review the evidence for the use of standing
devices and orthoses in order to inform all stakeholders better, in-
cluding boys and men with DMD, clinicians, decision makers and
funders, and to guide future research.
O B J E C T I V E S
To assess the effects of standing devices and orthoses on muscu-
loskeletal impairments (such as pain, contracture, scoliosis devel-
opment, and bone density) in boys and men with DMD, and secon-
darily to determine their effect on quality of life, participation in ac-
tivities, and patient experience (satisfaction). We also considered
any adverse events associated with their use.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs) and quasi-RCTs
for inclusion. We included studies reported in full text, published as
an abstract only, or unpublished. We included data from non-ran-
domised studies in the discussion, but not in the results section of
the review. We placed no restrictions on date or language of publi-
cation.
Types of participants
We included both men and boys of any age with a confirmed diag-
nosis of DMD.
If a study had included only a subset of participants with DMD, we
would have included it only if it measured the primary outcome for
the DMD subset.
Types of interventions
We considered trials that compared any model of standing de-
vice or orthoses (HKAFO, KAFO or standing shell) with any other
comparison group, including no standing device, a different mod-
el of standing device (for example a tilt table versus a standing
frame), usual care, or an alternative form of assistive weight bear-
ing. Standing devices included all types of standing frames, tilt ta-
bles and standing wheelchairs. We considered the following orthot-
ic devices: HKAFO, KAFO and standing shells. We included any trial
that compared one model of standing modality to another. We al-
lowed co-interventions in cases where they were provided to each
group equally.
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Types of outcome measures
We did not use the outcomes listed here as eligibility criteria for this
review, but identified them as outcomes of interest within included
studies.
Primary outcomes
1. Change in range of joint movement (goniometry; Pandya 1985)
in the short term (baseline to 3 months), medium term (3 to 12
months) and long term (over 12 months).
Secondary outcomes
1. Musculoskeletal impairment: measured using validated scales
in the short term (baseline to 3 months), medium term (3 to 12
months) and long term (over 12 months). Musculoskeletal im-
pairment included pain (visual analogue scale (VAS); McCorma-
ck 1988).
2. Scoliosis: measured by scoliometer (Bunnell 1984), or by Cobb's
angle on X-ray (Wills 2007). Change in value from baseline to over
12 months.
3. Bone density: measured by duel-energy X-ray absorptiometry
(DEXA) of the lumber spine, femoral heads, or both (Mazess
1990); change in value from baseline to over 12 months.
4. Respiratory function: measured as per cent predicted forced vi-
tal capacity (FVC%); change in value from baseline to 3 to 12
months (Phillips 2001).
5. Participation: measured using validated scales such as Chil-
dren’s Assessment of Participation and Enjoyment (CAPE) (King
2004); change in baseline value in the short term (3 months),
medium term (3 to 12 months) and long term (over 12 months).
6. Quality of life: measured using validated scales such as the Indi-
vidualized Neuromuscular Quality of Life questionnaire (INQoL)
(Vincent 2007), or Child Health Questionnaire (CHQ) (Landgraf
1999); measured by change in value in the short term (3 months),
medium term (3 to 12 months) and long term (over 12 months).
7. Bowel function: measured by frequency of episodes of constipa-
tion (Lo Cascio 2014); measured by change in value in medium
term (from baseline to 3 to 12 months).
8. Participant and family satisfaction with the intervention: as-
sessed, for example, by self-report questionnaires; measured
by change of value from baseline in the short term (3 months),
medium term (3 to 12 months) and long term (over 12 months).
We did not include qualitative reporting of participant satisfac-
tion.
9. Adverse events: subdivided into any adverse events, adverse
events that led to discontinuation of treatment, and serious ad-
verse events (events that were fatal, life threatening, or required
prolonged hospitalisation).
Search methods for identification of studies
Electronic searches
The Trials Search Co-ordinator searched the following databases
(detailed strategies are in the appendices):
1. the Cochrane Neuromuscular Specialised Register (Cochrane
Register of Studies (CRS Web) 5 September 2019 (CRS Web; Ap-
pendix 1);
2. the Cochrane Central Register of Controlled Trials (CENTRAL) 5
September 2019 (CRS Web; Appendix 2);
3. MEDLINE Ovid (January 1966 to 4 September 2019; Appendix 3);
4. Embase Ovid (1947 to 4 September 2019; Appendix 4);
5. CINAHL Plus EBSCOhost (Cumulative Index to Nursing and Allied
Health Literature; 1937 to 4 September 2019; Appendix 5);
6. AMED Ovid (Allied and Complementary Medicine; 1985 to August
week 4 2019; Appendix 6);
7. PsycINFO Ovid (1806 to August 2019; Appendix 7);
8. ProQuest Dissertations & Theses Global (1861 to August 2019;
Appendix 8).
We also searched the Physiotherapy Evidence Database (PEDro;
1929 to September 2019; Appendix 9), the United States Nation-
al Institutes of Health Clinical Trials Registry (www.ClinicalTrial-
s.gov; Appendix 10), and the World Health Organization Interna-
tional Clinical Trials Registry Portal (apps.who.int/trialsearch/; Ap-
pendix 10).
We searched all databases from their inception to the present, and
imposed no restriction on language of publication.
We identified non-randomised studies for inclusion in the discus-
sion from the same search results.
Searching other resources
We searched reference lists of all primary studies and review arti-
cles for additional references. We search relevant manufacturers'
websites for trial information (Higgins 2011).
We searched grey literature to identify other studies.
Data collection and analysis
Selection of studies
Two review authors (KP, SMcD) independently screened titles and
abstracts of all the studies identified as a result of the searches, and
coded them as 'retrieve' (eligible or potentially eligible/unclear) or
'do not retrieve'. We retrieved full-text study reports for potential-
ly eligible studies. Two review authors (KP, SMcD) independently
screened the full texts to identify studies eligible for inclusion, and
identified and recorded reasons for exclusion of the ineligible stud-
ies. There were no disagreements between the authors. We report-
ed the selection process in sufficient detail to complete a PRISMA
flow diagram (Figure 1) and 'Characteristics of excluded studies' ta-
ble.
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Figure 1.   Study flow diagram.
 
No studies met the inclusion criteria for this review.
Appendix 11 describes the data collection methods we will use,
should studies become available in future.
R E S U L T S
Description of studies
Results of the search
The search identified 90 citations (Figure 1). After duplicate re-
moval, we screened the titles and abstracts of 57 citations and ex-
cluded 44 records. We excluded studies if they were not RCTs or
quasi-RCTs, if they described surgical interventions, or if DMD was
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not the study population. We obtained 13 full-text studies, as it was
unclear from their titles and abstracts whether or not they met the
study criteria. All of these studies were non-RCTs; nine were cohort
studies, one was a qualitative study, one was a review paper, one
was a case series, and one was a consecutive sample. Furthermore,
most did not have a control group for comparison. We found no on-
going studies. After assessment of the full-text reports, we found no
studies that met the criteria for this review. Searches of the trials
registries retrieved no records.
Included studies
No studies met the review's inclusion criteria.
Excluded studies
We have listed all 13 papers reviewed in full text as excluded stud-
ies, as they did not meet the inclusion criteria (Characteristics of
excluded studies). Eleven of the studies did not focus on standing
or include at least one outcome of interest. Two studies were inter-
vention studies with a minimum of one outcome of interest (Taktak
1995; Townsend 2016). We have described them in the Agreements
and disagreements with other studies or reviews section below.
Risk of bias in included studies
No studies met the review's inclusion criteria.
EAects of interventions
No studies met the review's inclusion criteria.
D I S C U S S I O N
Summary of main results
After completing a comprehensive search, we identified no RCTs
that focussed on the use of standing devices for boys or adults with
DMD.
When reviewing the full-text of the 13 excluded studies, the authors
(KP, SMcD, and CK) identified a set of inclusion criteria to allow iden-
tification of studies which, in our opinion, could potentially inform
future trial design. These criteria identified studies that presented
experimental data, i.e. where boys or men with DMD experienced
different forms of standing devices or a standing device versus con-
trol, and studies that included a minimum of one outcome of in-
terest. We found two studies that met these criteria (Taktak 1995;
Townsend 2016). We have discussed them narratively below.
Overall completeness and applicability of evidence
We did not identify any RCTs that met the inclusion criteria for the
review. We identified two non-RCTs that reported outcomes of in-
terest, including range of joint movement, bone density, participa-
tion and family satisfaction (Taktak 1995; Townsend 2016). Neither
study included our other outcomes of interest, namely; bowel func-
tion, scoliosis, pain, quality of life, or respiratory function.
Quality of the evidence
This review did not find any studies that met the inclusion criteria.
The current literature surrounding standing frames and orthoses
for DMD lacks the robust methods of RCT designs. RCTs are needed
to enhance the overall quality of evidence.
Potential biases in the review process
The review process did not allow for the explicit identification of
potential adverse events. The main limitation of this review was the
lack of RCTs.
Agreements and disagreements with other studies or
reviews
This review has similar findings to other reviews on the topic of
management of DMD. Cheuk 2015, a Cochrane Review of surgery for
scoliosis, also included no studies due to a lack of RCTs in the area.
Our searches identified two non-randomised studies that present-
ed experimental data. The evidence described narratively below is
of very low-certainty, due to small sample size and lack of randomi-
sation. It should be interpreted with caution.
Evidence from non-randomised studies
Study design, participants and interventions
The studies were non-randomised; one was a within-group com-
parison (Taktak 1995), the other a case series (Townsend 2016).
Both studies had very few participants: four in Townsend 2016 and
26 in Taktak 1995. The boys participating were aged between 5 and
15 years, which explained the great variability in their stages of dis-
ease progression. At the start of each study, there was a mixed pre-
sentation of boys who were ambulant and boys who were non-
ambulant. Neither study reported whether boys had previously re-
ceived, or were currently receiving, steroid treatment (Townsend
2016; Taktak 1995).
The standing device used in Taktak 1995 was a knee-ankle-foot-or-
thosis (KAFO), whereas Townsend 2016 studied the effects of using
a standing wheelchair.
Outcomes of interest
Both studies reported a limited number of outcomes which aligned
to the specified focus of this review (Taktak 1995; Townsend 2016).
However, it was not clear whether the reported outcomes reflected
the effects of the standing device, or natural disease progression.
Change in joint range of movement
Townsend 2016 reported a change in range of joint movement for
the four participants after 6 to 20 months' use of a standing wheel-
chair (total 47 hours to 192 hours). The study reported range of
movement for the ankle joint (plantar flexor length), knee (popliteal
angle) and hip (Thomas test position) using goniometry over a pe-
riod of 6.5 to 20 months.
For hip range of movement, three boys showed improvements
(ranging from 9º to 15º), with the fourth boy showing a decrease in
range of movement (of 16º).
For the ankle joint, plantar flexor length was stable in three boys
and decreased in one boy. Two of the boys who had a stable an-
kle joint range of movement had recently undergone surgery for
Achilles tendon lengthening.
Knee flexor length improved in two boys (ranging from 1º to 6º) and
declined in two boys (ranging from 10º to 30º)
Taktak 1995 did not report change in joint movement.
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Pain
Neither study reported pain as an outcome.
Scoliosis
Neither study recorded scoliosis.
Bone density
One study measured bone density, both before and after use of a
standing wheelchair (47 to 192 hours' use over 6 to 12 months). The
study used a DEXA scan at the lumbar spine region for all four par-
ticipants (Townsend 2016).
Three boys showed a significant decrease in bone density during
the study period, and one boy's bone density remained stable. Two
boys showed an initial decrease in bone density between baseline
and mid-intervention (four months) before returning to baseline
levels at the point of intervention withdrawal (eight months). One
boy had an initial decrease in lumbar spine bone mineral densi-
ty from baseline to mid-intervention, which continued to decrease
over the study period. This boy was the only participant who lost
ambulation during the intervention period.
Taktak 1995 did not report bone density.
Respiratory function
Neither study recorded respiratory function.
Participation
One study recorded participation at eight months, using subjective
methods (Townsend 2016). Types of enhanced participation includ-
ed allowing access to eat breakfast with siblings (one participant),
accessing the freezer more readily (three participants), ability to ac-
cess higher shelves (one participant), standing to urinate (one par-
ticipant) and playing catch with the dog (one participant).
The following factors limited adherence during the study: device
malfunction (two participants), vacation (one participant), back
pain (one participant), ankle pain (one participant), limited time
(two participants), and motivation (four participants). The study re-
ported that standing tolerance within a given session was limited
due to plantar foot paraesthesia (one participant), knee or shin dis-
comfort (three participants), low back pain (one participant), foot
pressure (one participant) and leg fatigue (four participants).
Taktak 1995 did not report participation measures.
Quality of life
Neither study reported quality of life.
Bowel function
Neither study reported bowel function.
Participant and family satisfaction
One study recorded participant and family satisfaction using a
study-specific questionnaire (Taktak 1995).
All eight participants reported that a modular KAFO provided a bet-
ter cosmetic effect than the traditional KAFO. All participants re-
ported little or no difference in relation to the comfort of the two
devices, and five participants reported that they preferred the mod-
ular KAFO in terms of weight. Two participants reported increased
independence in relation to putting on and taking oH the modular
KAFO, in comparison to the traditional devices.
Adverse events
Neither study reported any adverse events.
Standard of care guidelines
The standard of care guidelines for Duchenne muscular dystrophy
have recently been updated (Birnkrant 2018a; Birnkrant 2018b).
These standards are based on expert consensus. These guidelines
recommend the use of passive or motorised supported standing
devices for prevention of contracture and deformity when stand-
ing in good alignment becomes difficult, and if contractures are not
too severe to prevent positioning or tolerance (Birnkrant 2018a).
Standing devices are also recommended in the early non-ambula-
tory stage to initiate a standing programme. The guidelines recom-
mend using standing programmes with caution in the late non-am-
bulatory stage (Birnkrant 2018b).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We lack evidence from randomised controlled trials (RCTs) to eval-
uate the effectiveness of standing devices in boys and men with
Duchenne muscular dystrophy.
Implications for research
We need further studies to investigate the effectiveness of stand-
ing devices in this population. Due to the ethical considerations
of removing a standing device, it may be more appropriate to ran-
domise to different types of standing devices. It would also be pos-
sible to use randomised controlled trial methods to determine the
optimal ‘dose’ of standing device use, and investigate the opti-
mum age range for the intervention. Other studies should inves-
tigate strategies to increase adherence and maintain motivation
for standing programmes. Future studies should use valid and reli-
able outcome measures that are clinically relevant. Future studies
should also include carefully designed control groups to determine
which elements of the intervention are influencing the outcome,
i.e. the standing device or other therapy techniques.
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DMD: Duchenne muscular dystrophy
KAFO: knee ankle foot orthosis
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Appendix 1. Cochrane Neuromuscular Specialised Register (CRSWeb) search strategy
Search date: 5 September 2019
#1 duchenne AND INREGISTER
#2 standing NEAR3 frame* AND INREGISTER
#3 standing NEAR3 device* AND INREGISTER
#4 (stand or standing) NEAR3 support* AND INREGISTER
#5 stander AND INREGISTER
#6 standing NEAR3 wheelchair* AND INREGISTER
#7 (stand or standing) NEAR3 aid* AND INREGISTER
#8 kafo* AND INREGISTER
#9 knee ankle foot ortho* AND INREGISTER
#10 assist* NEAR3 stand* AND INREGISTER
#11 loss NEAR3 stand* AND INREGISTER
#12 tilt* table* AND INREGISTER
#13 "orthotic device" or "orthotic devices" or brace or braces AND INREGISTER
#14 #13 and (stand or standing) AND INREGISTER
#15 #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #14 AND INREGISTER
#16 #1 and #15 AND INREGISTER
Appendix 2. Cochrane central Register of Controlled Studies (CENTRAL) (CRSWeb) search strategy
Search date 5 September 2019
#1 duchenne AND CENTRAL:TARGET
#2 standing NEAR3 frame* AND CENTRAL:TARGET
#3 standing NEAR3 device* AND CENTRAL:TARGET
#4 (stand or standing) NEAR3 support* AND CENTRAL:TARGET
#5 stander AND CENTRAL:TARGET
#6 standing NEAR3 wheelchair* AND CENTRAL:TARGET
#7 (stand or standing) NEAR3 aid* AND CENTRAL:TARGET
#8 kafo* AND CENTRAL:TARGET
#9 knee ankle foot ortho* AND CENTRAL:TARGET
#10 assist* NEAR3 stand* AND CENTRAL:TARGET
#11 loss NEAR3 stand* AND CENTRAL:TARGET
#12 tilt* table* AND CENTRAL:TARGET
#13 "orthotic device" or "orthotic devices" or brace or braces AND CENTRAL:TARGET
#14 #13 and (stand or standing) AND CENTRAL:TARGET
#15 #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #14 AND CENTRAL:TARGET
#16 #1 and #15 AND CENTRAL:TARGET
Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily (1946 to September 04, 2019)
Search Strategy:
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1 randomized controlled trial.pt. (488652)
2 controlled clinical trial.pt. (93265)
3 randomi#ed.tw. (583721)
4 placebo.ab. (200473)
5 drug therapy.fs. (2136487)
6 randomly.ab. (317408)
7 trial.ab. (475229)
8 groups.ab. (1949928)
9 or/1-8 (4540624)
10 exp animals/ not humans.sh. (4615097)
11 9 not 10 (3933179)
12 Muscular Dystrophy, Duchenne/ (5059)
13 duchenne.tw. (10686)
14 or/12-13 (11618)
15 (standing adj3 frame$).mp. (127)
16 (standing adj3 device$).mp. (131)
17 ((stand or standing) adj3 support$2).mp. (647)
18 stander.mp. (111)
19 (standing adj3 wheelchair$1).mp. (29)
20 (stand$3 adj3 aid$1).mp. (365)
21 kafo$1.mp. (82)
22 knee ankle foot ortho$.mp. (199)
23 (assist$ adj3 stand$3).mp. (761)
24 (loss adj3 stand$3).mp. (739)
25 tilt$ table$.mp. (3291)
26 Orthotic Devices/ (6250)
27 braces/ (5334)
28 brace$1.tw. (6343)
29 26 or 27 or 28 (14911)
30 29 and (stand or standing).mp. (568)
31 or/15-25,30 (6795)
32 11 and 14 and 31 (6)
33 14 and 31 (30)
34 remove duplicates from 33 (30)
Appendix 4. Embase (OvidSP) search strategy
Database: Embase (1974 to 2019 September 04)
Search Strategy:
1 crossover-procedure.sh. (60577)
2 double-blind procedure.sh. (165194)
3 single-blind procedure.sh. (36475)
4 randomized controlled trial.sh. (568805)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1685633)
6 trial.ti. (280325)
7 or/1-6 (1863745)
8 exp animal/ or exp invertebrate/ or animal.hw. or non human/ or nonhuman/ (26434028)
9 human/ or human cell/ or human tissue/ or normal human/ (20194559)
10 8 not 9 (6303486)
11 7 not 10 (1643351)
12 limit 11 to (conference abstracts or embase) (1380034)
13 Duchenne muscular dystrophy/ (15436)
14 Duchenne.tw. (14836)
15 13 or 14 (18690)
16 (standing adj3 frame$).mp. (229)
17 (standing adj3 device$).mp. (139)
18 (standing adj3 support$2).mp. (599)
19 stander.mp. (259)
20 exp foot orthosis/ (2978)
21 orthotics/ (3685)
22 brace/ (8859)
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23 (or/20-22) and (stand or standing).mp. (955)
24 or/16-19,23 (2089)
25 12 and 15 and 24 (1)
26 15 and 24 (20)
27 remove duplicates from 26 (20)
28 limit 27 to (conference abstracts or embase) (18)
Appendix 5. CINAHL Plus (EBSCOhost) search strategy
Friday, September 06, 2019 10:36:25 AM
S41 S20 and S37 12
S40 S38 AND S39 1
S39 EM 20180301- 635,649
S38 S19 AND S20 AND S37 5
S37 S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S36 5,286
S36 S35 and (stand or standing) 891
S35 S33 OR S34 13,625
S34 brace or braces 2,421
S33 orthotic device* or orthos* 12,564
S32 tilt* table* 908
S31 loss N3 stand* 368
S30 assist* N3 stand* 1,814
S29 knee ankle foot ortho* 152
S28 kafo* 59
S27 stand* N3 aid* 838
S26 standing N3 wheelchair* 27
S25 stander 52
S24 (stand or standing) N3 support* 275
S23 standing N3 device* 56
S22 standing N3 frame* 71
S21 standing frames 67
S20 Duchenne and dystroph* 1,897
S19 S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 1,264,592
S18 ABAB design* 121
S17 TI random* or AB random* 299,617
S16 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial or
sham? or dummy) ) 597,547
S15 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or experi-
ment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 231,767
S14 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 85,194
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S13 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind* or mask*) )
45,616
S12 PT ("clinical trial" or "systematic review") 166,169
S11 (MH "Factorial Design") 1,139
S10 (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") 393,415
S9 (MH "Meta Analysis") 39,710
S8 (MH "Solomon Four-Group Design") or (MH "Static Group Comparison") 98
S7 (MH "Quasi-Experimental Studies") 11,183
S6 (MH "Placebos") 11,443
S5 (MH "Double-Blind Studies") or (MH "Triple-Blind Studies") 42,452
S4 (MH "Clinical Trials+") 266,130
S3 (MH "Crossover Design") 17,909
S2 (MH "Random Assignment") or (MH "Random Sample") or (MH "Simple Random Sample") or (MH "Stratified Random Sample") or (MH
"Systematic Random Sample") 93,606
S1 (MH "Crossover Design") 17,909
Appendix 6. AMED (OvidSP) search strategy
Database: AMED (Allied and Complementary Medicine) (1985 to August 2019)
Search Strategy:
1 Randomized controlled trials/ (2251)
2 Random allocation/ (323)
3 Double blind method/ (732)
4 Single-Blind Method/ (137)
5 exp Clinical Trials/ (4110)
6 (clin$ adj25 trial$).tw. (7582)
7 ((singl$ or doubl$ or treb$ or trip$) adj25 (blind$ or mask$ or dummy)).tw. (3187)
8 placebos/ (626)
9 placebo$.tw. (3396)
10 random$.tw. (19575)
11 research design/ (2003)
12 Prospective Studies/ (1320)
13 meta analysis/ (299)
14 (meta?analys$ or systematic review$).tw. (4280)
15 control$.tw. (38515)
16 (multicenter or multicentre).tw. (1127)
17 ((study or studies or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).tw. (14048)
18 or/1-17 (59676)
19 (muscular dystrophy and duchenne).mp. (245)
20 (standing adj3 frame$).mp. (28)
21 (standing adj3 device$).mp. (26)
22 ((stand or standing) adj3 support$2).mp. (72)
23 stander.mp. (2)
24 (standing adj3 wheelchair$1).mp. (10)
25 (stand$3 adj3 aid$1).mp. (16)
26 kafo$1.mp. (31)
27 knee ankle foot ortho$.mp. (65)
28 (assist$ adj3 stand$3).mp. (67)
29 (loss adj3 stand$3).mp. (20)
30 tilt$ table$.mp. (47)
31 exp orthotic devices/ (2118)
32 brace$1.mp. (759)
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33 31 or 32 (2502)
34 33 and (stand or standing).mp. (153)
35 or/20-30,34 (457)
36 18 and 19 and 35 (3)
37 19 and 35 (8)
Appendix 7. PsycINFO (OvidSP) search strategy
Database: PsycINFO (1806 to August Week 4 2019)
Search Strategy:
1 (random$ or rct or cct or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$)
or assign$ or allocat$ or volunteer$).tw. (341095)
2 (duchenne adj5 dystroph$).mp. (632)
3 (standing adj3 frame$).mp. (31)
4 (standing adj3 device$).mp. (9)
5 ((stand or standing) adj3 support$2).mp. (175)
6 stander.mp. (28)
7 (standing adj3 wheelchair$1).mp. (7)
8 (stand$3 adj3 aid$1).mp. (78)
9 kafo$1.mp. (2)
10 knee ankle foot ortho$.mp. (3)
11 (assist$ adj3 stand$3).mp. (92)
12 (loss adj3 stand$3).mp. (126)
13 tilt$ table$.mp. (187)
14 orthotic device$.mp. (174)
15 brace$1.mp. (343)
16 14 or 15 (513)
17 16 and (stand or standing).mp. (32)
18 or/4-13,17 (727)
19 1 and 2 and 18 (0)
20 2 and 18 (0)
Appendix 8. ProQuest Dissertations & Theses Global search strategy
Search date 5 September 2019
all(standing OR stand OR stander) AND all(duchenne) AND all(KAFO OR "knee ankle foot orthosis" OR "tilt table" OR "orthotic device*" OR
brace OR Braces OR wheelchair) AND (randomized OR randomised OR randomly) = 1 result.
Appendix 9. PEDro search strategy
Duchenne = 27 results. 0 selected to follow up based on title and abstract.
Appendix 10. Clinical trial registry databases
Duchenne and standing and orthosis. 0 results.
Appendix 11. Additional methods
The following are additional methods as specified in our protocol. We did not employ them in the review owing to the absence of included
studies.
Data collection and analysis
Selection of studies
Two review authors (KP, SMcD) will independently screen titles and abstracts of all the potential studies we identify as a result of the
search for inclusion and code them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We will identify and exclude
duplicates and collate multiple reports of the same study so that each study rather than each report is the unit of interest in the review.
We will retrieve full-text study reports, and two review authors (KP, SMcD) will independently screen the full text and identify studies for
inclusion, and identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreements through discussion
or, if required, through consultation with a third review author (CK). We will report the selection process in sufficient detail to complete a
PRISMA flow diagram and 'Characteristics of excluded studies' table.
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Data extraction and management
We will use a data extraction form to extract study characteristics and outcome data; we will pilot this form on at least one study in the
review. Two review authors (KP, CK) will extract study characteristics from included studies. We will note if any outcome data were not
reported in a usable way. We will extract the following study characteristics.
1. Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, with-
drawals and date of study
2. Participants: N, mean age, age range, gender, current residential country, severity of condition, diagnostic criteria, baseline character-
istics, inclusion criteria and exclusion criteria
3. Interventions: intervention, number in each intervention group, comparison, concomitant medications and excluded medications
4. Outcomes: primary and secondary outcomes specified and collected and time points reported.
5. Results or main findings: primary and secondary results at all time points. Main findings will also report the number of previous fractures
and the age at which scoliosis surgery was completed.
6. Others: conflicts of interest among main investigators and study funding source(s)
We will resolve disagreements by consensus or by involving a third person (SL). One review author (KP) will transfer data into Review
Manager (Revman 2014). A second review author will check the outcome data entries (CK). A third review author (SL) will spot-check study
characteristics for accuracy against the trial report.
When reports require translation, the translator will extract data directly using a data extraction form, or review authors will extract data
from the translation provided. Where possible, a review author will check numerical data in the translation against the study report.
Assessment of risk of bias in included studies
Two review authors (KP, SL) will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). These authors will resolve disagreements by discussion or by involving another review
author (SMcD).
We will assess the risk of bias according to the following domains: random sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other bias.
We will grade each potential source of bias as high, low, or unclear and provide a quote from the study report together with a justification
for our judgment in the 'Risk of bias' table. We will summarise the risk of bias judgements across different studies for each of the domains
listed. We will consider blinding separately for different key outcomes where necessary (for example for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for a patient-reported pain scale). Where information on risk of bias relates
to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table. When considering treatment effects, we
will take into account the risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol and report any deviations from it in the 'Differences between protocol
and review' section of the systematic review.
Measures of treatment e!ect
We will analyse dichotomous data as risk ratios with 95% confidence interval (CI) and continuous data as mean difference with 95% CI,
or standardised mean difference with 95% CI for results across studies with outcomes that are conceptually the same, but measured in
different ways. We will enter data presented as a scale with a consistent direction of effect.
We will undertake meta-analyses only where this is meaningful, that is if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and interquartile ranges.
Where a single trial reports multiple trial arms, we will include only the relevant arms.
Unit of analysis issues
We do not expect to have any cross-over or cluster-randomised controlled trials, and therefore do not expect any unit-of-analysis issues
arising from these designs. If we do include a cross-over study, then, due to the progressive nature of DMD, we will analyse only the first arm
if the treatment arm precedes the control. If a study has more than one treatment arm (for example standing frame A versus control and
standing frame B versus control), and the study did not combine the active treatment arms for analysis, we will split the control treatment
arm between active treatment arms to avoid double-counting.
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Dealing with missing data
We will contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where
possible (for example, when a study is available as an abstract only). Where this is not possible, and it is thought that the missing data
introduces serious bias, we will use a sensitivity analysis to explore the impact of including such studies in the overall assessment of results.
We will report and compare descriptively the characteristics of studies with missing outcome data with the characteristics of complete
studies.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity among the trials in each analysis. If we identify substantial unexplained heterogeneity,
we will report both fixed-effect and random-effects results and explore possible causes by prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine a funnel plot to explore possible small-study biases. To further
determine reporting bias, we will request study protocols and use the ORBIT framework to examine the impact of selective reporting bias.
Data synthesis
We will use a fixed-effect model, providing there is no evidence of heterogeneity of effect. We will use a random-effects model if there is
evidence of statistical heterogeneity.
If the review includes more than one comparison that cannot be included in the same analysis, we will report the results for each com-
parison separately.
'Summary of findings' table
We will create a 'Summary of findings' table using the following outcomes.
1. Goniometry, change in value from baseline to 12 months
2. Pain (VAS), change in value from baseline to three months
3. Scoliosis (scoliometer), change in value from baseline to over 12 months
4. Bone density (DEXA), change in value from baseline to over 12 months
5. Respiratory function (FVC%), change in value from baseline to six to nine months
6. Quality of life (INQoL), change in value from baseline to 12 months
7. Adverse events
We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to as-
sess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We will use methods and recommen-
dations described in Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) using GRADEpro software
(GRADEpro GDT). We will justify all decisions to down- or upgrade the quality of studies using footnotes, and we will make comments to
aid readers' understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Dosage of standing frame or orthoses use.
2. Age of participant (0 to 12 years, 13 to 17 years, 18 years plus).
We will use the formal test for subgroup interactions in Review Manager (Revman 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Repeat the analysis excluding any unpublished studies.
2. Repeat the analysis excluding studies at high risk of bias.
3. If there are one or more very large studies, repeat the analysis excluding those studies to explore to what degree they dominate the
results.
Reaching conclusions
We will base our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We will
avoid making recommendations for practice, and our implications for research will suggest priorities for future research and outline the
remaining uncertainties in the area.
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IB: protocol development, development of the final review.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We did not implement the methods specified in our protocol for data extraction and analysis because the review included no eligible stud-
ies. We therefore could not complete various methods, including: data extraction, 'Risk of bias' assessment, measurement of treatment
effect, assessment of heterogeneity and reporting bias, data synthesis or sensitivity analysis. We were unable to complete a 'Summary of
findings' table or complete subgroup analysis. Appendix 11 details additional methods planned in the protocol.
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